Centre Testing International Grp (300012) Report Interpretation

Overview

This earnings review covers Centre Testing International Group’s in-line 1H26 results and Citi’s increased confidence that growth can sustain into 2H26 and beyond. Citi maintains Buy and a Rmb24 target price, supported by growth drivers, improving operating leverage and valuation analysis.

Core views

CTI reported 1H26 revenue of Rmb3,429m, up 15.9% year on year, and attributable net profit of Rmb563.7m, up 20.6%, broadly in line with the Rmb564m midpoint of preliminary guidance. Recurring net profit increased 20.3% after excluding Rmb35.0m of one-off gains, compared with Rmb27.9m a year earlier. Although 2Q26 net-profit growth slowed to 16.4% from 30.9% in 1Q26, Citi attributes the earlier quarter’s pace partly to a low base and notes that 2Q still maintained mid-teens growth. Revenue growth was steady at 15.6% in 2Q versus 16.2% in 1Q, and Citi expects 3Q revenue growth to retain momentum on easier comparisons. The report says the results increase confidence in Citi’s forecast of about 16% revenue growth and 20% net-profit growth for 2026. Its growth thesis rests on strategic emerging businesses—semiconductor-chip testing, AI compliance and hardware validation, low-carbon/ESG certification, and low-altitude-economy and new-energy applications—becoming additional growth curves. Citi also expects overseas expansion across Europe, Southeast Asia and Africa to unlock international-trade and supply-chain-compliance demand. Most acquired overseas operations have been consolidated since 4Q25, and Citi estimates they can provide at least 5 percentage points of CTI’s 15% full-year revenue-growth target. Recovering CRO pharmaceutical research, medical-device testing and specialized consumer-goods verification are cited as near-term catalysts. Margin improvement is a second analytical pillar. Citi models net margin rising from 15.4% in 2025 to 16.9% in 2028E. It sees further gross-margin recovery from Pharmacy and Medical, Consumption through an automotive-margin recovery and semiconductor turnaround, and auto testing. In 1H26, gross margin declined year on year in Life Science by 1.3 percentage points to 49.86%, Industrial testing by 1.5 points to 41.9%, and Trade Protection testing by 1.6 points to 71.2%; these segments accounted for 42%, 21% and 14% of sales, respectively. By contrast, Consumption and Pharmacy and Medical gross margins rose 5.4 points and 9.1 points to 46.8% and 28.5%, respectively, on 17% and 6% of sales. Citi expects Pharmacy and Medical margins to move closer to the group average as the business gains scale. The report also points to operating leverage and cash conversion. In 2Q, selling expenses rose 5.4% year on year against revenue growth of 15.9%, reducing the selling-expense ratio by 150bp to 15.2% of revenue and lifting net margin by 65bp to 16.4%. Administrative expenses rose 26.3% and R&D expenses 22.4%, outpacing revenue and adding roughly 100bp combined, reflecting M&A integration and new-laboratory spending. Accounts receivable were Rmb2,235m, up 8.0% from year-end, while operating cash flow of Rmb437.6m covered 78% of 1H net profit. CTI maintained an interim dividend of Rmb0.05 per share, or Rmb84m in total. Citi values CTI at Rmb24 using 33x FY26E P/E, a 0.5 standard-deviation discount to the historical mean, reflecting a projected three-year EPS CAGR of 19% through 2027E. Management’s approximately 15% 2026 revenue-growth guidance was raised from 10%, and Citi considers 1Q26’s 16% revenue growth supportive of that objective. As a cross-check, its DCF gives a Rmb25 fair value, using an 8.5% cost of equity, comprising a 3% risk-free return, 8% market premium and 1.2x beta; a 3.0% post-tax cost of debt; and 2% terminal growth. Citi links the terminal-growth assumption to developed-market industry growth and to stricter Chinese regulations and product-quality standards supporting TIC demand.

Analysis framework

Citi first compares reported 1H26 and quarterly results with preliminary guidance and recent growth rates. It then assesses growth by business drivers, overseas acquisitions and end-market recovery, evaluates segment margins, expense leverage and cash conversion, and values the company using FY26E P/E with a DCF cross-check.

Methodology notes

• Valuation methodsP/E and PEG Valuation

  Forward P/E valuation

  Citi applies 33x FY26E P/E, at 0.5 standard deviations below CTI’s historical mean, to derive its Rmb24 target price.

• Valuation methodsDCF (Discounted Cash Flow)

  DCF cross-check

  Citi discounts expected cash flows using its stated cost of equity, post-tax cost of debt and terminal-growth assumptions, producing a Rmb25 fair value.

• Industry AnalysisVolume-price decomposition

  Revenue growth and margin analysis by segment

  The report separates revenue growth, segment gross margins and operating expenses to explain the path to higher profitability.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Centre Testing International Grp (300012.SZ)

  Primary covered company; Citi expects emerging testing businesses, overseas expansion and recovering specialized sectors to support growth.

  Strengths

  In-line 1H26 execution, expanding strategic testing areas, overseas acquired-asset contribution, and operating leverage.

  Weaknesses

  Some core segment gross margins declined in 1H26; administrative and R&D expenses grew faster than revenue.

  Comparison

  Citi states that forward P/E and P/B are trading well below their historical means.

  Risks

  Unfavorable policy changes, weaker revenue growth from a market downturn, rising labor and rental costs, and M&A failures.

Key data

• 1H26 revenueRmb3,429m; +15.9% yoyReported first-half revenue growth.
• 1H26 attributable net profitRmb563.7m; +20.6% yoyBroadly in line with Rmb564m midpoint preliminary guidance.
• 2Q26 net-profit growth+16.4% yoySlower than 1Q26’s 30.9% growth but still mid-teens.
• 2026 growth forecast~16% revenue growth / ~20% net-profit growthCiti’s forecast following in-line 1H26 results.
• 2028E net margin16.9%Citi forecast, versus 15.4% in 2025.
• Target valuationRmb24 at 33x FY26E P/E0.5 standard deviations below historical mean; DCF cross-check is Rmb25.

Impact & implications

Citi argues that steady revenue growth, contributions from acquired overseas businesses, emerging testing categories and margin recovery support its 2026–27 earnings outlook. The report views the valuation as supported by both forward P/E and DCF methods.

Risks

• Unfavorable policy changes could prevent the stock from reaching Citi’s target price.
• A market downturn and contraction could slow revenue growth.
• Labor and rental costs could rise faster than expected.
• M&A execution could fail.

What to watch

• 3Q revenue growth momentum, which Citi expects to benefit from easier comparisons.
• Contribution from overseas acquisitions, expected to provide at least 5 percentage points of the 15% full-year revenue-growth target.
• Recovery in Consumption and Pharmacy and Medical margins, including automotive and semiconductor testing.
• Progress in emerging testing areas and specialized sectors such as CRO and medical-device testing.